Dan Liu
Research Areas
Pharmacology of Traditional Chinese Medicine; Anti-inflammatory and Immunopharmacology; Tumor Pharmacology
Education
1996.9–2001.7: Jiangxi Medical College, Clinical Medicine, M.B.
2003.9–2006.7: School of Pharmacy, Nanchang University, M.M.
2006.9–2009.7: Nanchang University, Surgery, Ph.D.
2009.10–2012.10: Jiangxi Provincial People’s Hospital, Postdoctoral Fellow
2014.5–2015.5: Boston University, United States, Visiting Scholar
Professional Experience
2001.7–present: School of Pharmacy, Nanchang University
Academic Service
Member, Chinese Pharmacological Society
Member, Teaching and Popular Science Committee of the Chinese Pharmacological Society
Executive Member, International Education Committee for Foreign Students of the Chinese Pharmacological Society
Major Achievements
Principal investigator of five projects funded by the National Natural Science Foundation of China (NSFC); principal investigator of three provincial Natural Science Foundation projects; and principal investigator of one key project from the Administration of Traditional Chinese Medicine. Published over 60 academic papers in leading domestic and international journals, including more than 40 SCI-indexed articles. Co-authored three books published by the People’s Medical Publishing House and Higher Education Press.
1. NSFC Projects Led as Principal Investigator
(1) NSFC Regional Project (82560807) “Mechanistic Study of Xiao-Chai-Hu Decoction in Improving Sepsis-Induced Acute Liver Injury” Funding: ¥320,000; Period: 2026–2029.
(2) NSFC Regional Project (81760587)
“Role of the Bcl-2/VDAC1-Mediated Mitochondrial Apoptotic Pathway in Taurine’s Protection Against Iron Overload-Induced Liver Injury”
Funding: ¥350,000; Period: 2018–2021.
(3) NSFC Regional Project (81460551)
“Role of the 14-3-3ε/GSK3/β-catenin Pathway in Cross-Tolerance to Myocardial Ischemia/Reperfusion Injury during Endotoxin Tolerance”
Funding: ¥550,000; Period: 2015–2018.
(4) NSFC Young Scientist Fund (81100104)
“Mechanisms of AMPKα2 Subcellular Localization in Chloride-Mediated Myocardial Ischemia/Reperfusion Injury”
Funding: ¥200,000; Period: 2012–2014.
(4) NSFC Regional Project (30860271)
“Explosive ROS Generation, Target Pathways, and Dynamic Chloride Ion Changes in Myocardial Ischemia/Reperfusion Injury” Funding: ¥250,000; Period: 2009–2011.
2. Representative Publications in the Past Five Years
(1) Shang Z, Zhou L, Liu Y, Yang X, Yao D, Zhai F, Liu B, Chen Y, Zhu X, Liu D, Yi B. Tongxie Yaofang attenuates ulcerative colitis by modulating gut microbiota and IL-10RA/NF-κB-mediated macrophage polarization. Phytomedicine. 2025; 148: 157459.
(2) Qiao Y, Lai S, Wang Y, Hu F, Liu Y, Zhai F, Zhang Z, Liu D, Huang H. Puerarin attenuates myocardial ischemia-reperfusion damage by targeting ferroptosis through 14-3-3ε modulation. Am J Chin Med. 2025:1–20.
(3) Zhang S, Li B, Han X, Ruan L, Fu X, Chen Y, Wan H, Zhu X, Liu D, Yi B. Sanren Decoction ameliorates ulcerative colitis by modulating gut microbiota and macrophage polarization to enhance intestinal barrier function. Chin Med. 2025; 20(1): 128.
(4) Zhou L, Liu Y, Zhai F, Liu B, Liu D, Yi B. Mechanisms of corn silk polysaccharide in promoting colorectal cancer progression: a multi-omics approach integrating microbiota, metabolomics, and transcriptomics. J Funct Foods. 2025; 130: 106937.
(5) Liu D, Lin S, Hu Y, Xiong J, Wan H, Chen Y, Ding T, Zhao H, Jiang R, Huang Z, Yao D, Li M, Zhu X, Yi B. HNRNPC stabilizes m6A-modified AC145207.5 to accelerate colorectal cancer tumorigenesis by impeding the Nrf2/GPX4 axis-mediated ferroptosis. Noncoding RNA Res. 2025; 13: 43-56.
(6) Zhao H, Fu X, Wang Y, Shang Z, Li B, Zhou L, Liu Y, Liu D, Yi B. Therapeutic potential of vanillic acid in ulcerative colitis through microbiota and macrophage modulation. Mol Nutr Food Res. 2025; 69(4): e202400785.
(7) Wang Y, Fu X, Shang Z, Qiao Y, Liu Y, Zhou L, Liu D. In vivo and in vitro study on the regulatory mechanism of Xiao-Chai-Hu Decoction on PANoptosis in sepsis-induced cardiomyopathy. J Ethnopharmacol. 2025; 336: 118740.
(8) Wang X, Liu R, Liu D. The role of the MAPK signaling pathway in cardiovascular disease: pathophysiological mechanisms and clinical therapy. Int J Mol Sci. 2025; 26(6): 2667.
(9) Wang X, Lang F, Liu D. High-salt diet and intestinal microbiota: influence on cardiovascular disease and inflammatory bowel disease. Biology (Basel). 2024; 13(9): 674.
(10) Jiang R, Ruan L, Ding T, Wan H, Chen Y, Zhu X, Huang Z, Yao D, Li M, Yi B, Liu D. Development of a prognostic gene signature and exploration of P4HA1 in the modulation of cuproptosis in colorectal cancer. Sci Rep. 2024; 14(1): 31766.
(11) Ding T, Shang Z, Zhao H, Song R, Xiong J, He C, Liu D, Yi B. Anoikis-related gene signatures in colorectal cancer: implications for cell differentiation, immune infiltration, and prognostic prediction. Sci Rep. 2024; 14(1): 11525.
(12) Zhao H, Ding T, Chen Y, Yang W, Rao J, Liu D, Yi B. Arecoline aggravates acute ulcerative colitis in mice by affecting intestinal microbiota and serum metabolites. Front Immunol. 2023; 14: 1197922.
(13) Zhang X, Zeng Z, Liu Y, Liu D. Emerging relevance of ghrelin in programmed cell death and its application in diseases. Int J Mol Sci. 2023; 24(24): 17254.
(14) Wan H, Liu X, Chen Y, Tang R, Yi B, Liu D. Silencing of the ARK5 gene reverses multidrug resistance in SGC7901/DDP gastric cancer cells. PeerJ. 2020; 8: e9560.
(15) Yao X, Jiao S, Qin M, Hu W, Yi B, Liu D. Vanillic acid alleviates acute myocardial hypoxia/reoxygenation injury by inhibiting oxidative stress. Oxid Med Cell Longev. 2020; 2020: 8348035.
Cn
